Replication of live attenuated cold-adapted H2N2 influenza virus vaccine candidates in non human primates.
Identifieur interne : 000061 ( PubMed/Checkpoint ); précédent : 000060; suivant : 000062Replication of live attenuated cold-adapted H2N2 influenza virus vaccine candidates in non human primates.
Auteurs : Andrew J. Broadbent [États-Unis] ; Celia P. Santos [États-Unis] ; Myeisha Paskel [États-Unis] ; Yumiko Matsuoka [États-Unis] ; Janine Lu [États-Unis] ; Zhongying Chen [États-Unis] ; Hong Jin [États-Unis] ; Kanta Subbarao [États-Unis]Source :
- Vaccine [ 1873-2518 ] ; 2015.
Descripteurs français
- KwdFr :
- Adaptation biologique, Animaux, Charge virale, Femelle, Glycoprotéine hémagglutinine du virus influenza (génétique), Macaca fascicularis, Macaca mulatta, Mâle, Protéines mutantes (génétique), Réplication virale, Sous-type H2N2 du virus de la grippe A (génétique), Sous-type H2N2 du virus de la grippe A (physiologie), Vaccins antigrippaux.
- MESH :
- génétique : Glycoprotéine hémagglutinine du virus influenza, Protéines mutantes, Sous-type H2N2 du virus de la grippe A.
- physiologie : Sous-type H2N2 du virus de la grippe A.
- Adaptation biologique, Animaux, Charge virale, Femelle, Macaca fascicularis, Macaca mulatta, Mâle, Réplication virale, Vaccins antigrippaux.
English descriptors
- KwdEn :
- Adaptation, Biological, Animals, Chlorocebus aethiops, Female, Hemagglutinin Glycoproteins, Influenza Virus (genetics), Influenza A Virus, H2N2 Subtype (genetics), Influenza A Virus, H2N2 Subtype (physiology), Influenza Vaccines, Macaca fascicularis, Macaca mulatta, Male, Mutant Proteins (genetics), Viral Load, Virus Replication.
- MESH :
- chemical , genetics : Hemagglutinin Glycoproteins, Influenza Virus, Mutant Proteins.
- genetics : Influenza A Virus, H2N2 Subtype.
- physiology : Influenza A Virus, H2N2 Subtype.
- Adaptation, Biological, Animals, Chlorocebus aethiops, Female, Influenza Vaccines, Macaca fascicularis, Macaca mulatta, Male, Viral Load, Virus Replication.
Abstract
The development of an H2N2 vaccine is a priority in pandemic preparedness planning. We previously showed that a single dose of a cold-adapted (ca) H2N2 live attenuated influenza vaccine (LAIV) based on the influenza A/Ann Arbor/6/60 (AA ca) virus was immunogenic and efficacious in mice and ferrets. However, in a Phase I clinical trial, viral replication was restricted and immunogenicity was poor. In this study, we compared the replication of four H2N2 LAIV candidate viruses, AA ca, A/Tecumseh/3/67 (TEC67 ca), and two variants of A/Japan/305/57 (JAP57 ca) in three non-human primate (NHP) species: African green monkeys (AGM), cynomolgus macaques (CM) and rhesus macaques (RM). One JAP57 ca virus had glutamine and glycine at HA amino acid positions 226 and 228 (Q-G) that binds to α2-3 linked sialic acids, and one had leucine and serine that binds to α2-3 and α2-6 linked residues (L-S). The replication of all ca viruses was restricted, with low titers detected in the upper respiratory tract of all NHP species, however replication was detected in significantly more CMs than AGMs. The JAP57 ca Q-G and TEC67 ca viruses replicated in a significantly higher percentage of NHPs than the AA ca virus, with the TEC67 ca virus recovered from the greatest percentage of animals. Altering the receptor specificity of the JAP57 ca virus from α2-3 to both α2-3 and α2-6 linked sialic acid residues did not significantly increase the number of animals infected or the titer to which the virus replicated. Taken together, our data show that in NHPs the AA ca virus more closely reflects the human experience than mice or ferret studies. We suggest that CMs and RMs may be the preferred species for evaluating H2N2 LAIV viruses, and the TEC67 ca virus may be the most promising H2N2 LAIV candidate for further evaluation.
DOI: 10.1016/j.vaccine.2014.10.065
PubMed: 25444799
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:25444799Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Replication of live attenuated cold-adapted H2N2 influenza virus vaccine candidates in non human primates.</title><author><name sortKey="Broadbent, Andrew J" sort="Broadbent, Andrew J" uniqKey="Broadbent A" first="Andrew J" last="Broadbent">Andrew J. Broadbent</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea><wicri:noRegion>MD</wicri:noRegion></affiliation></author><author><name sortKey="Santos, Celia P" sort="Santos, Celia P" uniqKey="Santos C" first="Celia P" last="Santos">Celia P. Santos</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea><wicri:noRegion>MD</wicri:noRegion></affiliation></author><author><name sortKey="Paskel, Myeisha" sort="Paskel, Myeisha" uniqKey="Paskel M" first="Myeisha" last="Paskel">Myeisha Paskel</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea><wicri:noRegion>MD</wicri:noRegion></affiliation></author><author><name sortKey="Matsuoka, Yumiko" sort="Matsuoka, Yumiko" uniqKey="Matsuoka Y" first="Yumiko" last="Matsuoka">Yumiko Matsuoka</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea><wicri:noRegion>MD</wicri:noRegion></affiliation></author><author><name sortKey="Lu, Janine" sort="Lu, Janine" uniqKey="Lu J" first="Janine" last="Lu">Janine Lu</name><affiliation wicri:level="1"><nlm:affiliation>MedImmune LLC, Mountain View, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>MedImmune LLC, Mountain View, CA</wicri:regionArea><wicri:noRegion>CA</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Zhongying" sort="Chen, Zhongying" uniqKey="Chen Z" first="Zhongying" last="Chen">Zhongying Chen</name><affiliation wicri:level="1"><nlm:affiliation>MedImmune LLC, Mountain View, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>MedImmune LLC, Mountain View, CA</wicri:regionArea><wicri:noRegion>CA</wicri:noRegion></affiliation></author><author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name><affiliation wicri:level="1"><nlm:affiliation>MedImmune LLC, Mountain View, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>MedImmune LLC, Mountain View, CA</wicri:regionArea><wicri:noRegion>CA</wicri:noRegion></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: ksubbarao@niaid.nih.gov.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea><wicri:noRegion>MD</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25444799</idno><idno type="pmid">25444799</idno><idno type="doi">10.1016/j.vaccine.2014.10.065</idno><idno type="wicri:Area/PubMed/Corpus">000088</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000088</idno><idno type="wicri:Area/PubMed/Curation">000088</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000088</idno><idno type="wicri:Area/PubMed/Checkpoint">000061</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000061</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Replication of live attenuated cold-adapted H2N2 influenza virus vaccine candidates in non human primates.</title><author><name sortKey="Broadbent, Andrew J" sort="Broadbent, Andrew J" uniqKey="Broadbent A" first="Andrew J" last="Broadbent">Andrew J. Broadbent</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea><wicri:noRegion>MD</wicri:noRegion></affiliation></author><author><name sortKey="Santos, Celia P" sort="Santos, Celia P" uniqKey="Santos C" first="Celia P" last="Santos">Celia P. Santos</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea><wicri:noRegion>MD</wicri:noRegion></affiliation></author><author><name sortKey="Paskel, Myeisha" sort="Paskel, Myeisha" uniqKey="Paskel M" first="Myeisha" last="Paskel">Myeisha Paskel</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea><wicri:noRegion>MD</wicri:noRegion></affiliation></author><author><name sortKey="Matsuoka, Yumiko" sort="Matsuoka, Yumiko" uniqKey="Matsuoka Y" first="Yumiko" last="Matsuoka">Yumiko Matsuoka</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea><wicri:noRegion>MD</wicri:noRegion></affiliation></author><author><name sortKey="Lu, Janine" sort="Lu, Janine" uniqKey="Lu J" first="Janine" last="Lu">Janine Lu</name><affiliation wicri:level="1"><nlm:affiliation>MedImmune LLC, Mountain View, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>MedImmune LLC, Mountain View, CA</wicri:regionArea><wicri:noRegion>CA</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Zhongying" sort="Chen, Zhongying" uniqKey="Chen Z" first="Zhongying" last="Chen">Zhongying Chen</name><affiliation wicri:level="1"><nlm:affiliation>MedImmune LLC, Mountain View, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>MedImmune LLC, Mountain View, CA</wicri:regionArea><wicri:noRegion>CA</wicri:noRegion></affiliation></author><author><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name><affiliation wicri:level="1"><nlm:affiliation>MedImmune LLC, Mountain View, CA, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>MedImmune LLC, Mountain View, CA</wicri:regionArea><wicri:noRegion>CA</wicri:noRegion></affiliation></author><author><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name><affiliation wicri:level="1"><nlm:affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: ksubbarao@niaid.nih.gov.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD</wicri:regionArea><wicri:noRegion>MD</wicri:noRegion></affiliation></author></analytic><series><title level="j">Vaccine</title><idno type="eISSN">1873-2518</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adaptation, Biological</term><term>Animals</term><term>Chlorocebus aethiops</term><term>Female</term><term>Hemagglutinin Glycoproteins, Influenza Virus (genetics)</term><term>Influenza A Virus, H2N2 Subtype (genetics)</term><term>Influenza A Virus, H2N2 Subtype (physiology)</term><term>Influenza Vaccines</term><term>Macaca fascicularis</term><term>Macaca mulatta</term><term>Male</term><term>Mutant Proteins (genetics)</term><term>Viral Load</term><term>Virus Replication</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adaptation biologique</term><term>Animaux</term><term>Charge virale</term><term>Femelle</term><term>Glycoprotéine hémagglutinine du virus influenza (génétique)</term><term>Macaca fascicularis</term><term>Macaca mulatta</term><term>Mâle</term><term>Protéines mutantes (génétique)</term><term>Réplication virale</term><term>Sous-type H2N2 du virus de la grippe A (génétique)</term><term>Sous-type H2N2 du virus de la grippe A (physiologie)</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Hemagglutinin Glycoproteins, Influenza Virus</term><term>Mutant Proteins</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Glycoprotéine hémagglutinine du virus influenza</term><term>Protéines mutantes</term><term>Sous-type H2N2 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Sous-type H2N2 du virus de la grippe A</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Influenza A Virus, H2N2 Subtype</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adaptation, Biological</term><term>Animals</term><term>Chlorocebus aethiops</term><term>Female</term><term>Influenza Vaccines</term><term>Macaca fascicularis</term><term>Macaca mulatta</term><term>Male</term><term>Viral Load</term><term>Virus Replication</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adaptation biologique</term><term>Animaux</term><term>Charge virale</term><term>Femelle</term><term>Macaca fascicularis</term><term>Macaca mulatta</term><term>Mâle</term><term>Réplication virale</term><term>Vaccins antigrippaux</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The development of an H2N2 vaccine is a priority in pandemic preparedness planning. We previously showed that a single dose of a cold-adapted (ca) H2N2 live attenuated influenza vaccine (LAIV) based on the influenza A/Ann Arbor/6/60 (AA ca) virus was immunogenic and efficacious in mice and ferrets. However, in a Phase I clinical trial, viral replication was restricted and immunogenicity was poor. In this study, we compared the replication of four H2N2 LAIV candidate viruses, AA ca, A/Tecumseh/3/67 (TEC67 ca), and two variants of A/Japan/305/57 (JAP57 ca) in three non-human primate (NHP) species: African green monkeys (AGM), cynomolgus macaques (CM) and rhesus macaques (RM). One JAP57 ca virus had glutamine and glycine at HA amino acid positions 226 and 228 (Q-G) that binds to α2-3 linked sialic acids, and one had leucine and serine that binds to α2-3 and α2-6 linked residues (L-S). The replication of all ca viruses was restricted, with low titers detected in the upper respiratory tract of all NHP species, however replication was detected in significantly more CMs than AGMs. The JAP57 ca Q-G and TEC67 ca viruses replicated in a significantly higher percentage of NHPs than the AA ca virus, with the TEC67 ca virus recovered from the greatest percentage of animals. Altering the receptor specificity of the JAP57 ca virus from α2-3 to both α2-3 and α2-6 linked sialic acid residues did not significantly increase the number of animals infected or the titer to which the virus replicated. Taken together, our data show that in NHPs the AA ca virus more closely reflects the human experience than mice or ferret studies. We suggest that CMs and RMs may be the preferred species for evaluating H2N2 LAIV viruses, and the TEC67 ca virus may be the most promising H2N2 LAIV candidate for further evaluation. </div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25444799</PMID><DateCompleted><Year>2015</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Replication of live attenuated cold-adapted H2N2 influenza virus vaccine candidates in non human primates.</ArticleTitle><Pagination><MedlinePgn>193-200</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2014.10.065</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(14)01455-8</ELocationID><Abstract><AbstractText>The development of an H2N2 vaccine is a priority in pandemic preparedness planning. We previously showed that a single dose of a cold-adapted (ca) H2N2 live attenuated influenza vaccine (LAIV) based on the influenza A/Ann Arbor/6/60 (AA ca) virus was immunogenic and efficacious in mice and ferrets. However, in a Phase I clinical trial, viral replication was restricted and immunogenicity was poor. In this study, we compared the replication of four H2N2 LAIV candidate viruses, AA ca, A/Tecumseh/3/67 (TEC67 ca), and two variants of A/Japan/305/57 (JAP57 ca) in three non-human primate (NHP) species: African green monkeys (AGM), cynomolgus macaques (CM) and rhesus macaques (RM). One JAP57 ca virus had glutamine and glycine at HA amino acid positions 226 and 228 (Q-G) that binds to α2-3 linked sialic acids, and one had leucine and serine that binds to α2-3 and α2-6 linked residues (L-S). The replication of all ca viruses was restricted, with low titers detected in the upper respiratory tract of all NHP species, however replication was detected in significantly more CMs than AGMs. The JAP57 ca Q-G and TEC67 ca viruses replicated in a significantly higher percentage of NHPs than the AA ca virus, with the TEC67 ca virus recovered from the greatest percentage of animals. Altering the receptor specificity of the JAP57 ca virus from α2-3 to both α2-3 and α2-6 linked sialic acid residues did not significantly increase the number of animals infected or the titer to which the virus replicated. Taken together, our data show that in NHPs the AA ca virus more closely reflects the human experience than mice or ferret studies. We suggest that CMs and RMs may be the preferred species for evaluating H2N2 LAIV viruses, and the TEC67 ca virus may be the most promising H2N2 LAIV candidate for further evaluation. </AbstractText><CopyrightInformation>Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Broadbent</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Celia P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paskel</LastName><ForeName>Myeisha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matsuoka</LastName><ForeName>Yumiko</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Janine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>MedImmune LLC, Mountain View, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhongying</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>MedImmune LLC, Mountain View, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jin</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>MedImmune LLC, Mountain View, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subbarao</LastName><ForeName>Kanta</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. Electronic address: ksubbarao@niaid.nih.gov.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>ZIA AI000933-10</GrantID><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019267">Hemagglutinin Glycoproteins, Influenza Virus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050505">Mutant Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000220" MajorTopicYN="Y">Adaptation, Biological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019267" MajorTopicYN="N">Hemagglutinin Glycoproteins, Influenza Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053121" MajorTopicYN="N">Influenza A Virus, H2N2 Subtype</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="Y">Influenza Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008252" MajorTopicYN="N">Macaca fascicularis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050505" MajorTopicYN="N">Mutant Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="N">Viral Load</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">H2N2</Keyword><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">LAIV</Keyword><Keyword MajorTopicYN="N">Monkey</Keyword><Keyword MajorTopicYN="N">Non-human primate</Keyword><Keyword MajorTopicYN="N">Vaccine</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>05</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>09</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25444799</ArticleId><ArticleId IdType="pii">S0264-410X(14)01455-8</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2014.10.065</ArticleId><ArticleId IdType="pmc">PMC4259263</ArticleId><ArticleId IdType="mid">NIHMS639708</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Gen Virol. 1999 Dec;80 ( Pt 12):3167-71</Citation><ArticleIdList><ArticleId IdType="pubmed">10567648</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Med. 2000;51:407-21</Citation><ArticleIdList><ArticleId IdType="pubmed">10774473</ArticleId></ArticleIdList></Reference><Reference><Citation>Avian Dis. 2003;47(3 Suppl):931-3</Citation><ArticleIdList><ArticleId IdType="pubmed">14575089</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1971 Sep;94(3):280-9</Citation><ArticleIdList><ArticleId IdType="pubmed">4328569</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 1993 Jun;194(2):781-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7684877</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Virol. 1994;135(1-2):101-14</Citation><ArticleIdList><ArticleId IdType="pubmed">8198436</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1997 Aug;176 Suppl 1:S14-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9240688</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1998 Jul;178(1):53-60</Citation><ArticleIdList><ArticleId IdType="pubmed">9652423</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2006 Mar 23;440(7083):435-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16554799</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2007 Jan 18;445(7125):319-23</Citation><ArticleIdList><ArticleId IdType="pubmed">17230189</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2010 Aug;84(15):7695-702</Citation><ArticleIdList><ArticleId IdType="pubmed">20504935</ArticleId></ArticleIdList></Reference><Reference><Citation>Avian Dis. 2007 Mar;51(1 Suppl):425-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17494599</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2007 Nov;3(11):e167</Citation><ArticleIdList><ArticleId IdType="pubmed">17997603</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20949-54</Citation><ArticleIdList><ArticleId IdType="pubmed">18093945</ArticleId></ArticleIdList></Reference><Reference><Citation>Virus Genes. 2008 Aug;37(1):16-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18454312</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Sep 8;26(38):4940-6</Citation><ArticleIdList><ArticleId IdType="pubmed">18662737</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2009 Mar 4;301(9):945-53</Citation><ArticleIdList><ArticleId IdType="pubmed">19255113</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3455-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19218453</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Aug 20;460(7258):1021-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19672242</ArticleId></ArticleIdList></Reference><Reference><Citation>Virology. 2010 Mar 1;398(1):109-14</Citation><ArticleIdList><ArticleId IdType="pubmed">20034647</ArticleId></ArticleIdList></Reference><Reference><Citation>Vet Pathol. 2010 Nov;47(6):1040-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20647595</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 Feb;85(3):1214-23</Citation><ArticleIdList><ArticleId IdType="pubmed">21084481</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2011 Mar 10;471(7337):157-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21390107</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2011 Jun 10;29(26):4322-7</Citation><ArticleIdList><ArticleId IdType="pubmed">21513761</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2011 Aug;85(16):8133-40</Citation><ArticleIdList><ArticleId IdType="pubmed">21680506</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Vaccines. 2011 Aug;10(8):1131-41</Citation><ArticleIdList><ArticleId IdType="pubmed">21854309</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2012 Mar;86(5):2780-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22190726</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2012 Aug 17;30(38):5603-10</Citation><ArticleIdList><ArticleId IdType="pubmed">22789506</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Host Microbe. 2012 Oct 18;12(4):598-604</Citation><ArticleIdList><ArticleId IdType="pubmed">23084925</ArticleId></ArticleIdList></Reference><Reference><Citation>Influenza Other Respir Viruses. 2013 Jan;7(1):66-73</Citation><ArticleIdList><ArticleId IdType="pubmed">22417012</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2013 Mar;9(3):e1003223</Citation><ArticleIdList><ArticleId IdType="pubmed">23516363</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2014 Jan;88(2):1175-88</Citation><ArticleIdList><ArticleId IdType="pubmed">24227848</ArticleId></ArticleIdList></Reference><Reference><Citation>J Virol. 2014 Jul;88(14):8139-52</Citation><ArticleIdList><ArticleId IdType="pubmed">24807726</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>États-Unis</li></country></list><tree><country name="États-Unis"><noRegion><name sortKey="Broadbent, Andrew J" sort="Broadbent, Andrew J" uniqKey="Broadbent A" first="Andrew J" last="Broadbent">Andrew J. Broadbent</name></noRegion><name sortKey="Chen, Zhongying" sort="Chen, Zhongying" uniqKey="Chen Z" first="Zhongying" last="Chen">Zhongying Chen</name><name sortKey="Jin, Hong" sort="Jin, Hong" uniqKey="Jin H" first="Hong" last="Jin">Hong Jin</name><name sortKey="Lu, Janine" sort="Lu, Janine" uniqKey="Lu J" first="Janine" last="Lu">Janine Lu</name><name sortKey="Matsuoka, Yumiko" sort="Matsuoka, Yumiko" uniqKey="Matsuoka Y" first="Yumiko" last="Matsuoka">Yumiko Matsuoka</name><name sortKey="Paskel, Myeisha" sort="Paskel, Myeisha" uniqKey="Paskel M" first="Myeisha" last="Paskel">Myeisha Paskel</name><name sortKey="Santos, Celia P" sort="Santos, Celia P" uniqKey="Santos C" first="Celia P" last="Santos">Celia P. Santos</name><name sortKey="Subbarao, Kanta" sort="Subbarao, Kanta" uniqKey="Subbarao K" first="Kanta" last="Subbarao">Kanta Subbarao</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000061 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000061 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:25444799
|texte= Replication of live attenuated cold-adapted H2N2 influenza virus vaccine candidates in non human primates.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:25444799" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a H2N2V1
| This area was generated with Dilib version V0.6.33. |  |